COMETRIQ, known generically as cabozantinib, is a prescription medication designed for the treatment of certain types of cancer. It is specifically indicated for the treatment of advanced medullary thyroid cancer, renal cell carcinoma (kidney cancer), and hepatocellular carcinoma (a form of liver cancer) in patients who have previously received other forms of treatment. COMETRIQ works by inhibiting multiple tyrosine kinases, which are enzymes known to promote tumor growth and angiogenesis (the formation of new blood vessels that supply tumors with nutrients). By blocking these pathways, COMETRIQ can slow or stop the growth of cancer cells and reduce the supply of nutrients to tumors, thereby inhibiting their progression. Due to its mechanism of action and potential side effects, the use of COMETRIQ requires careful monitoring by a healthcare professional.